NASDAQ:XON - Intrexon News Headlines

$6.42
+0.17 (+2.72 %)
(As of 09/15/2019 05:39 AM ET)
Today's Range
$6.23
Now: $6.42
$6.4250
50-Day Range
$5.51
MA: $6.63
$8.33
52-Week Range
$3.95
Now: $6.42
$19.94
Volume287,420 shs
Average Volume1.05 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Headlines

Intrexon (NASDAQ XON) News Headlines

Source:
DateHeadline
Intrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) Head-To-Head ReviewIntrexon (NASDAQ:XON) versus US Stem Cell (NASDAQ:USRM) Head-To-Head Review
www.americanbankingnews.com - September 13 at 12:25 PM
$32.16 Million in Sales Expected for Intrexon Corp (NASDAQ:XON) This Quarter$32.16 Million in Sales Expected for Intrexon Corp (NASDAQ:XON) This Quarter
www.americanbankingnews.com - September 12 at 7:35 AM
-$0.24 Earnings Per Share Expected for Intrexon Corp (NASDAQ:XON) This Quarter-$0.24 Earnings Per Share Expected for Intrexon Corp (NASDAQ:XON) This Quarter
www.americanbankingnews.com - September 10 at 4:18 AM
Intrexon Corp (NASDAQ:XON) Receives Consensus Rating of "Hold" from BrokeragesIntrexon Corp (NASDAQ:XON) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 3 at 6:19 AM
Teladoc Gains on Growing Acceptance for TeleHealth Services - Yahoo FinanceTeladoc Gains on Growing Acceptance for TeleHealth Services - Yahoo Finance
finance.yahoo.com - August 29 at 5:36 PM
Financial Review: Intrexon (NASDAQ:XON) & BIOQUAL (NASDAQ:BIOQ)Financial Review: Intrexon (NASDAQ:XON) & BIOQUAL (NASDAQ:BIOQ)
www.americanbankingnews.com - August 24 at 6:31 PM
Intrexon (XON) Subsidiary ActoBio Therapeutics Grantef IND Green Light for New Antigen-Specific Immunotherapy Study - StreetInsider.comIntrexon (XON) Subsidiary ActoBio Therapeutics Grantef IND Green Light for New Antigen-Specific Immunotherapy Study - StreetInsider.com
www.streetinsider.com - August 19 at 10:06 AM
Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77% - Yahoo FinanceIntroducing Intrexon (NASDAQ:XON), The Stock That Tanked 77% - Yahoo Finance
finance.yahoo.com - August 19 at 10:06 AM
Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77%Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77%
finance.yahoo.com - August 19 at 10:06 AM
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients Tolerance of GlutenActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
finance.yahoo.com - August 19 at 10:06 AM
Bullish Options Positioning in Intrexon (XON) Targets Upside in Shares Above $10 -Susquehanna - StreetInsider.comBullish Options Positioning in Intrexon (XON) Targets Upside in Shares Above $10 -Susquehanna - StreetInsider.com
www.streetinsider.com - August 14 at 5:36 PM
Intrexon Corp (XON) Q2 2019 Earnings Call Transcript - Yahoo FinanceIntrexon Corp (XON) Q2 2019 Earnings Call Transcript - Yahoo Finance
finance.yahoo.com - August 12 at 10:21 AM
Intrexon Corp (XON) Q2 2019 Earnings Call TranscriptIntrexon Corp (XON) Q2 2019 Earnings Call Transcript
www.fool.com - August 12 at 3:35 AM
Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMTEdited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT
finance.yahoo.com - August 11 at 9:14 AM
Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT - Yahoo FinanceEdited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT - Yahoo Finance
finance.yahoo.com - August 10 at 11:53 PM
Intrexon Corporation 2019 Q2 - Results - Earnings Call Slides - Seeking AlphaIntrexon Corporation 2019 Q2 - Results - Earnings Call Slides - Seeking Alpha
seekingalpha.com - August 10 at 10:29 AM
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2 - Yahoo FinanceIntrexon (XON) Reports Narrower-Than-Expected Loss in Q2 - Yahoo Finance
finance.yahoo.com - August 10 at 10:29 AM
Intrexon Corp (XON) CEO Randal Kirk on Q2 2019 Results - Earnings Call Transcript - Seeking AlphaIntrexon Corp (XON) CEO Randal Kirk on Q2 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 5:11 AM
Intrexon Reports Second Quarter and First Half 2019 Financial Results - PRNewswireIntrexon Reports Second Quarter and First Half 2019 Financial Results - PRNewswire
www.prnewswire.com - August 9 at 5:11 AM
Intrexon Reports Second Quarter and First Half 2019 Financial ResultsIntrexon Reports Second Quarter and First Half 2019 Financial Results
finance.yahoo.com - August 9 at 5:11 AM
First Week of September 20th Options Trading For Intrexon CorpFirst Week of September 20th Options Trading For Intrexon Corp
www.nasdaq.com - August 7 at 10:58 AM
Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosing in Phase 1 Study of PRGN-3005 UltraCAR-T - StreetInsider.comIntrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosing in Phase 1 Study of PRGN-3005 UltraCAR-T - StreetInsider.com
www.streetinsider.com - August 5 at 10:10 AM
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal CancerPrecigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
finance.yahoo.com - August 5 at 10:10 AM
Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline - Yahoo FinanceEarnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline - Yahoo Finance
finance.yahoo.com - August 1 at 5:44 PM
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th - Yahoo FinanceIntrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th - Yahoo Finance
finance.yahoo.com - August 1 at 5:44 PM
Earnings Preview: Intrexon (XON) Q2 Earnings Expected to DeclineEarnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline
finance.yahoo.com - August 1 at 5:44 PM
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th - PRNewswireIntrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th - PRNewswire
www.prnewswire.com - August 1 at 11:14 AM
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8thIntrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th
finance.yahoo.com - August 1 at 11:14 AM
Accellix, Inc Expands Leadership Team and Announces Name Change - Yahoo FinanceAccellix, Inc Expands Leadership Team and Announces Name Change - Yahoo Finance
finance.yahoo.com - July 25 at 8:21 AM
Heres Why Intrexon Jumped 58% in June - Yahoo FinanceHere's Why Intrexon Jumped 58% in June - Yahoo Finance
finance.yahoo.com - July 9 at 5:39 PM
Here's Why Intrexon Jumped 58% in JuneHere's Why Intrexon Jumped 58% in June
finance.yahoo.com - July 9 at 5:39 PM
Belgium : ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 DiabetesBelgium : ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
www.marketwatch.com - July 7 at 9:24 AM
What Does Intrexon Corporations (NASDAQ:XON) Balance Sheet Tell Us About It? - Yahoo FinanceWhat Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It? - Yahoo Finance
finance.yahoo.com - July 5 at 9:34 AM
What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It?What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It?
finance.yahoo.com - July 5 at 9:34 AM
Intrexon (XON) Subsidiary ActoBio Therapeutics Inc. Advances AG019 to Next Stage of Phase Ib/IIa Clinical Study - StreetInsider.comIntrexon (XON) Subsidiary ActoBio Therapeutics Inc. Advances AG019 to Next Stage of Phase Ib/IIa Clinical Study - StreetInsider.com
www.streetinsider.com - July 1 at 9:25 AM
ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 DiabetesActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
finance.yahoo.com - July 1 at 9:25 AM
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
finance.yahoo.com - June 26 at 5:34 PM
Intrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T - StreetInsider.comIntrexon (XON) Subsidiary Precigen Inc. Reports First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T - StreetInsider.com
www.streetinsider.com - June 26 at 10:21 AM
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra - Yahoo FinanceIntrexon Up on Striking 100M Cannabinoid Deal With Surterra - Yahoo Finance
finance.yahoo.com - June 19 at 11:08 AM
Why Intrexon Stock Popped Today - Yahoo FinanceWhy Intrexon Stock Popped Today - Yahoo Finance
finance.yahoo.com - June 19 at 11:08 AM
Intrexon Up on Striking 100M Cannabinoid Deal With SurterraIntrexon Up on Striking 100M Cannabinoid Deal With Surterra
finance.yahoo.com - June 19 at 11:08 AM
Visiongain Report Looks at Opportunities Within the $1bn Human Microbiome Therapeutics Market - Yahoo FinanceVisiongain Report Looks at Opportunities Within the $1bn Human Microbiome Therapeutics Market - Yahoo Finance
finance.yahoo.com - June 18 at 6:51 PM
Intrexon and Enlivex Therapeutics among healthcare gainers; ContraVir Pharmaceuticals leads the losers - Seeking AlphaIntrexon and Enlivex Therapeutics among healthcare gainers; ContraVir Pharmaceuticals leads the losers - Seeking Alpha
seekingalpha.com - June 18 at 6:51 PM
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production - Yahoo FinanceIntrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production - Yahoo Finance
finance.yahoo.com - June 18 at 6:51 PM
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid ProductionIntrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
finance.yahoo.com - June 18 at 6:51 PM
Intrexon Strikes $100M Partnership With Surterra For Cannabinoid ProductionIntrexon Strikes $100M Partnership With Surterra For Cannabinoid Production
finance.yahoo.com - June 18 at 6:51 PM
Why Intrexon Stock Popped TodayWhy Intrexon Stock Popped Today
finance.yahoo.com - June 18 at 6:51 PM
Intrexons Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference - Yahoo FinanceIntrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference - Yahoo Finance
finance.yahoo.com - June 13 at 10:09 AM
Intrexons Subsidiary Precigen to Present at the JMP Securities Life Sciences ConferenceIntrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 13 at 10:09 AM
Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of SharesIntrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares
finance.yahoo.com - June 11 at 10:35 AM
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Featured Article: Trading Strategy

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel